TrialAnnals of the rheumatic diseases2022

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

Richard A Furie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.